MedTrace Logo

Medication Exposure in Older Patients With Constitutional Hemorrhagic Disease

NCT04282486 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 142

Last updated 2021-07-13

No results posted yet for this study

Summary

The improvements observed in the care of patients with hemophilia or Willebrand disease have led to an increase in their life expectancy, which today approaches that of the general population. This increase in life expectancy leads in these patients to the development of comorbidities related to aging (cardiovascular and neurological diseases, cancers and kidney diseases) (e.g "Franchini \& Mannuccio", BJH, 2009). The care of these comorbidities represents a new challenge for the medical teams. Toward multiple comorbidities, polypharmacy is often associated.

Many studies about medication exposure and management in older patients were published but no study was conducted to explore the medication management of older patients with hemophilia or Willebrand disease.

Conditions

Interventions

OTHER

Telephone interview

Primary objective: potentially inappropriate medication prevalence Secondary objective: Number and type of medication Polypharmacy prevalence Medication regimen complexity using Medication Regimen Complexity Index Anticholinergic and sedative exposure using Drug Burden Index A telephone interview will be conducted with patients in order to collect medication data from medical prescriptions.

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Eligibility

Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-22
Primary Completion
2021-01-29
Completion
2021-01-29

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04282486 on ClinicalTrials.gov